BTIG keeps Buy ratings on Atlassian and Rapport Therapeutics
BTIG analysts maintained Buy ratings on Atlassian with a $260 target and Rapport Therapeutics with an $89 target. The data was published by TradingView, citing Benzinga.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, BTIG analysts kept their Buy rating on Atlassian shares and set a price target of $260. The target implies an upside of about 21.1% from the October 19 close of $214.75. The note points to cloud revenue running roughly $200 million above initial forecasts, and says new AI offerings, including Teamwork Graph and Rovo agents, should make the company's products more appealing to enterprise customers.
BTIG also maintained a Buy rating on Rapport Therapeutics with an $89 target, implying an 211.2% gain from the October 19 close of $28.60. The analysts said the lead asset, RAP-219, showed efficacy in treating bipolar mania, meeting its primary and secondary endpoints with a well-tolerated profile. Positive results came at a 0.75 mg daily dose, leaving room for higher dosing.
why it matters
Reports like these usually move sentiment around individual stocks rather than the broader market. For investors, the key items are Atlassian's revenue trend and the next results from the RAP-219 program, which will determine how well the analysts' targets hold up.
tags
instruments
sources
- BTIG maintains Buy rating on Atlassian, $260 price target — TradingView, 20 October 2026 at 10:23 UTC
- BTIG maintains Buy rating on Rapport Therapeutics, $89 price target — TradingView, 20 October 2026 at 11:24 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗